Published on Web 07/10/2009
Total Synthesis of (+)-Lyconadin A and Related Compounds
via Oxidative C-N Bond Formation
Scott P. West, Alakesh Bisai, Andrew D. Lim, Raja R. Narayan, and
Richmond Sarpong*
Department of Chemistry, UniVersity of California, Berkeley, California 94720
Received May 12, 2009; E-mail: rsarpong@berkeley.edu
Abstract: The formation of carbon-nitrogen (C-N) bonds is a fundamental bond construction in organic
synthesis and is indispensable for the synthesis of alkaloid natural products. In the context of the synthesis
of the architecturally complex Lycopodium alkaloid lyconadin A, we have discovered a highly efficient
oxidative C-N bond forming reaction that relies on the union of a nitrogen anion and a carbon anion.
Empirical evidence amassed during our synthetic studies suggests that the mechanism of the C-N bond
forming process encompasses polar as well as radical processes. Herein, we present our study of this
novel C-N bond forming reaction and its application to the enantioselective total synthesis of lyconadin A
and related derivatives.
Introduction
endeavors can play a critical role in the bioactivity elucidation
studies of the Lycopodium alkaloids by providing access to
Since the isolation of the first Lycopodium alkaloid natural
product (lycopodine (1, Figure 1)) by Bo¨deker in 18811 and
the structural elucidation of annotinine (2) by Wiesner in 1957,2
synthetic organic chemists have remained fascinated with
the architecture of this family of compounds. The majority of
these natural products are believed to arise in Nature from the
phlegmarine skeleton (see 3). The reigning postulate for the
biosynthesis of these compounds was advanced by Spenser3 and
is well described in the literature.4,5 Over the past three decades,
there has been an increase in the number and diversity of
alkaloids identified as constituents of the Lycopodium family.6
Several members, exemplified by huperzine A (4),7 have been
shown to be potent inhibitors of acetylcholinesterase and have
begun to find use in the treatment of Alzheimer’s disease in
China.8 In addition, biological activity ranging from neurotrophic
activity to anticancer properties has been reported for others in
this family.9
significant quantities of the natural products and related deriva-
tives. We have been interested in tracing the connections among
a subset of Lycopodium alkaloids referred to as the “miscel-
laneous” group10 because they possess unique frameworks
distinct from the traditional structural classes (i.e., lycopodine,
lycodine, and fawcettimine). The development of a unified
strategy for the synthesis of the “miscellaneous” group would
afford opportunities to study their biosynthetic relationships as
well as provide unambiguous structural characterization and
satisfactory quantities for biological studies.
On the basis of the structural resemblance between dihydro-
lycolucine (5), lucidine A (6), and oxolucidine A (7), we
reasoned that these compounds could arise synthetically from
a common precursor (8) related to the tetracyclic core of 5 via
a series of hydrogenation and/or oxygenation reactions. Impor-
tantly, installation of a C11-N bond (lucidine numbering; see
5)11 could offer an opportunity to access lyconadin A (9)12 and
related compounds such as lyconadin B (10).13 Moreover, in
line with the proposed biogenesis of spirolucidine (11) from an
oxolucidine relative,14 ring-contractive rearrangement of the
R-hydroxyimine moiety of 7 could form the spirotetracycle of
11. Additionally, the spirocyclic nankakurine skeleton (see 12),
Despite the reported bioactivity of select congeners, a
comprehensive biological screen of the majority of the Lyco-
podium alkaloids has yet to be undertaken. Total synthesis
(1) Bo¨deker, K. Ann. Chem. 1881, 208, 363.
(2) Wiesner, K.; Ayer, W. A.; Fowler, L. R.; Valenta, Z. Chem. Ind.
(London) 1957, 564–565.
(3) For leading references, see: (a) Castillo, M.; Gupta, R. N.; MacLean,
D. B.; Spenser, I. D. Can. J. Chem. 1970, 48, 1893–1903. (b) Castillo,
M.; Gupta, R. N.; Ho, Y. K.; MacLean, D. B.; Spenser, I. D. Can.
J. Chem. 1970, 48, 2911–2918. (c) Heimscheidt, T.; Spenser, I. D.
J. Am. Chem. Soc. 1993, 115, 3020–3021. (d) Heimscheidt, T.;
Spenser, I. D. J. Am. Chem. Soc. 1996, 118, 1799–1800.
(4) Ayer, W. A. Nat. Prod. Rep. 1991, 8, 455–463.
(8) Jiang, H.; Luo, X.; Bai, D. Curr. Med. Chem. 2003, 10, 2231–2252.
(9) For a recent review on Lycopodium alkaloids, which discusses their
biological activity in detail, see: Ma, X.; Gang, D. R. Nat. Prod. Rep.
2004, 21, 752–772.
(10) This word was introduced to describe a subset of Lycopodium alkaloids
of unclassified biogenesis. See ref 9.
(5) Ayer, W. A.; Trifonov, L. S. Lycopodium Alkaloids. In The Alkaloids;
Cordell, G. A., Brossi, A., Eds.; Academic Press: New York, 1994;
Vol. 45, pp 233-266.
(11) For lucidine numbering, see: 6 (Figure 1) and ref 9.
(12) Kobayashi, J.; Hirasawa, Y.; Yoshida, N.; Morita, H. J. Org. Chem.
2001, 66, 5901–5904.
(6) For a recent review, see: Hirasawa, Y.; Kobayashi, J.; Morita, H.
Heterocycles 2009, 77, 679–729.
(13) Ishiuchi, K.; Kubota, T.; Hoshino, T.; Obara, Y.; Nakahata, N.;
Kobayashi, J. Biorg. Med. Chem. 2006, 14, 5995–6000.
(14) (a) Tori, M.; Shimoji, T.; Takaoka, S.; Nakashima, K.; Sono, M.; Ayer,
W. A. Tetrahedron Lett. 1999, 40, 323–324. (b) Tori, M.; Shimoji,
T.; Shimura, E.; Takaoka, S.; Nakashima, K.; Sono, M.; Ayer, W. A.
Phytochemistry 2000, 53, 503–509.
(7) (a) Liu, J. S.; Zhu, Y. L.; Yu, C. M.; Zhou, Y. Z.; Han, Y. Y.; Wu,
F. W.; Qi, B. F. Can. J. Chem. 1986, 64, 837–839. (b) For a recent
review on huperzine A, see Ma, X.; Tan, C.; Zhu, D.; Gang, D. R.;
Xiao, P. J. Ethnopharmacol. 2007, 113, 15–34.
9
10.1021/ja903868n CCC: $40.75 2009 American Chemical Society
J. AM. CHEM. SOC. 2009, 131, 11187–11194 11187